Mineralys Therapeutics Inc. (NASDAQ: MLYS) completed enrollment in its Phase 2 EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe obstructive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE